COMPANY
Kartos Therapeutics
Timeline
- Trial start Phase 3: Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib source ↗
- Trial start Phase 2/Phase 3: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer source ↗
- Trial start Phase 1/Phase 2: Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer source ↗
- Trial start Phase 2: KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer source ↗
- Trial start Phase 1/Phase 2: KRT-232 and TKI Study in Chronic Myeloid Leukemia source ↗
- Trial start Phase 2: Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis source ↗
- Trial start Phase 1/Phase 2: Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL source ↗
- Trial start 1: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or source ↗
- Trial start Phase 1/Phase 2: KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF source ↗
- Trial start 1: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute My source ↗
- Trial start Phase 1/Phase 2: Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma source ↗
- Trial start Phase 2/Phase 3: KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment source ↗
- Trial start Phase 2: KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera source ↗
- Trial start 1: A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma source ↗
- Trial start 1: A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia source ↗
- Trial start 1: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma source ↗
Upcoming milestones
- Dec 31, 2026 (ESTIMATED) · Phase 3 · Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib · NCT06479135
Clinical trials (lead sponsor) 16
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06479135 | Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | Phase 3 | Recruiting | Jun 3, 2024 | Dec 31, 2026 (estimated) |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | Phase 2/Phase 3 | Recruiting | Jul 17, 2023 | 2025-08 (estimated) |
| NCT04113616 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | 1 | Terminated | Sep 25, 2019 | Sep 27, 2023 (actual) |
| NCT05705466 | Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer | Phase 1/Phase 2 | Withdrawn | 2023-06 | 2025-06 (estimated) |
| NCT05027867 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Phase 2 | Terminated | Dec 6, 2021 | Aug 26, 2022 (actual) |
| NCT03662126 | KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment | Phase 2/Phase 3 | Unknown status (ClinicalTrials.gov) | Jan 15, 2019 | Dec 31, 2023 (estimated) |
| NCT03787602 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | Phase 1/Phase 2 | Unknown status (ClinicalTrials.gov) | Mar 19, 2019 | 2024-11 (estimated) |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | Phase 1/Phase 2 | Recruiting | Feb 23, 2021 | 2022-10 (estimated) |
| NCT04485260 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib | 1 | Unknown status (ClinicalTrials.gov) | Jan 28, 2021 | 2022-10 (estimated) |
| NCT04878003 | Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis | Phase 2 | Unknown status (ClinicalTrials.gov) | Apr 13, 2021 | 2024-05 (estimated) |
| NCT04640532 | KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF | Phase 1/Phase 2 | Unknown status (ClinicalTrials.gov) | Nov 17, 2020 | May 11, 2022 (estimated) |
| NCT04835584 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | Phase 1/Phase 2 | Unknown status (ClinicalTrials.gov) | May 7, 2021 | Dec 31, 2024 (estimated) |
| NCT01723020 | A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | 1 | Completed | Dec 27, 2012 | Mar 15, 2017 (actual) |
| NCT02110355 | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | 1 | Completed | Dec 19, 2014 | Dec 27, 2018 (actual) |
| NCT03669965 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | Phase 2 | Active, not recruiting | Jan 15, 2019 | 2022-04 (estimated) |
| NCT02016729 | A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia | 1 | Completed | Apr 1, 2014 | Apr 19, 2017 (actual) |